Search

Your search keyword '"Wiviott, Stephen D."' showing total 678 results
Start Over Author "Wiviott, Stephen D." Search Limiters Full Text
678 results on '"Wiviott, Stephen D."'

1. Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials

Author

Marston, Nicholas A., Pirruccello, James P., Melloni, Giorgio E. M., Kamanu, Frederick, Bonaca, Marc P., Giugliano, Robert P., Scirica, Benjamin M., Wiviott, Stephen D., Bhatt, Deepak L., Steg, Philippe Gabriel, Raz, Itamar, Braunwald, Eugene, Libby, Peter, Ellinor, Patrick T., Bick, Alexander G., Sabatine, Marc S., and Ruff, Christian T.

Published
2024
Full Text
View/download PDF

6. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial

Author

Abtan, Jeremie, Wiviott, Stephen D., Sorbets, Emmanuel, Popovic, Batric, Elbez, Yedid, Mehta, Shamir R., Sabatine, Marc S., Bode, Christoph, Pollack, Charles V., Cohen, Marc, Moccetti, Tiziano, Laanmets, Peep, Faxon, David, Okreglicki, Andrzej, Ducrocq, Gregory, and Steg, Ph. Gabriel

Published
2021
Full Text
View/download PDF

7. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Author

Sabatine, Marc S, Giugliano, Robert P, Keech, Anthony C, Honarpour, Narimon, Wiviott, Stephen D, Murphy, Sabina A, Kuder, Julia F, Wang, Huei, Liu, Thomas, Wasserman, Scott M, Sever, Peter S, Pedersen, Terje R, and FOURIER Steering Committee and Investigators

Subjects
FOURIER Steering Committee and Investigators, Humans, Cardiovascular Diseases, Hypercholesterolemia, Antibodies, Monoclonal, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug Therapy, Combination, Incidence, Least-Squares Analysis, Follow-Up Studies, Double-Blind Method, Aged, Middle Aged, Female, Male, Atherosclerosis, Cholesterol, LDL, Antibodies, Monoclonal, Humanized, Proprotein Convertase 9, Cardiovascular, Clinical Research, Heart Disease - Coronary Heart Disease, Heart Disease, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundEvolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.MethodsWe conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years.ResultsAt 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P

Published
2017

10. Causes of late mortality with dual antiplatelet therapy after coronary stents

Author

Mauri, Laura, Elmariah, Sammy, Yeh, Robert W, Cutlip, Donald E, Steg, P Gabriel, Windecker, Stephan, Wiviott, Stephen D, Cohen, David J, Massaro, Joseph M, D'Agostino, Ralph B, Braunwald, Eugene, and Kereiakes, Dean J

Subjects
Cancer, Clinical Trials and Supportive Activities, Cardiovascular, Heart Disease, Heart Disease - Coronary Heart Disease, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aspirin, Cause of Death, Drug Therapy, Combination, Drug-Eluting Stents, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Neoplasms, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Pyridines, Treatment Outcome, Dual antiplatelet therapy, Mortality, Thienopyridine, DAPT Study Investigators, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsIn the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo. We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study.Methods and resultsPatients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months. A blinded independent adjudication committee evaluated deaths. Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16).ConclusionBleeding accounted for a minority of deaths among patients treated with continued thienopyridine. Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding. Caution is warranted when considering extended thienopyridine in patients with advanced cancer.Trial registrationclinicaltrials.gov Identifier: NCT00977938.

Published
2016

11. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61

Author

Patel, Siddharth M., primary, Morrow, David A., additional, Bellavia, Andrea, additional, Berg, David D., additional, Bhatt, Deepak L., additional, Jarolim, Petr, additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Raz, Itamar, additional, Steg, P. Gabriel, additional, Wilding, John P. H., additional, Sabatine, Marc S., additional, Wiviott, Stephen D., additional, Braunwald, Eugene, additional, Scirica, Benjamin M., additional, and Bohula, Erin A., additional

Published
2023
Full Text
View/download PDF

14. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.

Author

Patel, Siddharth M., Morrow, David A., Bellavia, Andrea, Berg, David D., Bhatt, Deepak L., Jarolim, Petr, Leiter, Lawrence A., McGuire, Darren K., Raz, Itamar, Steg, P. Gabriel, Wilding, John P.H., Sabatine, Marc S., Wiviott, Stephen D., Braunwald, Eugene, Scirica, Benjamin M., and Bohula, Erin A.

Subjects
DAPAGLIFLOZIN, BRAIN natriuretic factor, NATRIURETIC peptides, BODY mass index, HEART failure, HEART metabolism disorders, RISK assessment
Abstract

Aim: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT‐proBNP with respect to heart failure risk remains incompletely defined. Methods and results: Data were pooled across three randomized clinical trials enrolling predominantly patients who were overweight or obese with established cardiometabolic disease: SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61. Hospitalization for heart failure (HHF) was examined across strata of baseline BMI and NT‐proBNP. The effect of dapagliflozin versus placebo was assessed for a treatment interaction across BMI categories in patients with or without an elevated baseline NT‐proBNP (≥125 pg/ml). Among 24 455 patients, the median NT‐proBNP was 96 (interquartile range [IQR]: 43–225) pg/ml and the median BMI was 33 (IQR 29–37) kg/m2, with 68% of patients having a BMI ≥30 kg/m2. There was a significant inverse association between NT‐proBNP and BMI which persisted after adjustment for all clinical variables (p < 0.001). Within any range of NT‐proBNP, those at higher BMI had higher risk of HHF at 2 years (comparing BMI <30 vs. ≥40 kg/m2 for NT‐proBNP ranges of <125, 125–<450 and ≥450 pg/ml: 0.0% vs. 0.6%, 1.3% vs. 4.0%, and 8.1% vs. 13.8%, respectively), which persisted after multivariable adjustment (adjusted hazard ratio [HRadj] 7.47, 95% confidence interval [CI] 3.16–17.66, HRadj 3.22 [95% CI 2.13–4.86], and HRadj 1.87 [95% CI 1.35–2.60], respectively). In DECLARE‐TIMI 58, dapagliflozin versus placebo consistently reduced HHF across BMI categories in those with an elevated NT‐proBNP (p‐trend for HR across BMI = 0.60), with a pattern of greater absolute risk reduction (ARR) at higher BMI (ARR for BMI <30 to ≥40 kg/m2: 2.2% to 4.7%; p‐trend = 0.059). Conclusions: The risk of HHF varies across BMI categories for any given range of circulating NT‐proBNP. These findings showcase the importance of considering BMI when applying NT‐proBNP for heart failure risk stratification, particularly for patients with low‐level elevations in NT‐proBNP (125–<450 pg/ml) where there appears to be a clinically meaningful absolute and relative risk gradient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

Author

Moura, Filipe A., primary, Berg, David D., additional, Bellavia, Andrea, additional, Dwyer, Jamie P., additional, Mosenzon, Ofri, additional, Scirica, Benjamin M., additional, Wiviott, Stephen D., additional, Bhatt, Deepak L., additional, Raz, Itamar, additional, Feinberg, Mark W., additional, Braunwald, Eugene, additional, Morrow, David A., additional, and Sabatine, Marc S., additional

Published
2023
Full Text
View/download PDF

16. Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial

Author

Dillinger, Jean-Guillaume, Ducrocq, Gregory, Elbez, Yedid, Cohen, Marc, Bode, Christoph, Pollack, Charles, Jr, Petrauskiene, Birute, Henry, Patrick, Dorobantu, Maria, French, William J., Wiviott, Stephen D., Sabatine, Marc S., Mehta, Shamir R., and Steg, Philippe Gabriel

Published
2021
Full Text
View/download PDF

17. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Author

Schechter, Meir, Wiviott, Stephen D., Raz, Itamar, Goodrich, Erica L., Rozenberg, Aliza, Yanuv, Ilan, Murphy, Sabina, Zelniker, Thomas A., Fredriksson, Martin, Johansson, Peter A, Leiter, Lawrence A., Bhatt, Deepak, McGuire, Darren K, Wilding, John P. H., Gause-Nilson, Ingrid A. M., Cahn, Avivit, Langkilde, Anna Maria, Sabatine, Marc S., and Mosenzon, Ofri

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract

BackgroundIn people with type 2 diabetes at high risk of cardiovascular or kidney disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of hospitalisations for heart failure. Less is known about their effects on hospitalisation from any cause, especially in people with type 2 diabetes without atherosclerotic cardiovascular disease, which includes most of the global population of people with type 2 diabetes. We aimed to assess the effect of the SGLT2 inhibitor, dapagliflozin, on the risks of hospitalisations for any cause and for specific causes in people with type 2 diabetes with and without atherosclerotic cardiovascular disease.MethodsThe DECLARE-TIMI 58 trial was a double-blind, multicentre, randomised, placebo-controlled study. People with type 2 diabetes and either risk factors for or established atherosclerotic cardiovascular disease were randomly assigned (1:1) to receive oral dapagliflozin 10 mg or placebo once daily. In these post-hoc analyses, the effects of dapagliflozin on risks of first non-elective any-cause and cause-specific hospitalisation were assessed with Cox proportional hazards regression models overall and in the subset of participants without prevalent atherosclerotic cardiovascular disease. The risk of total (first plus subsequent) non-elective hospitalisations was assessed with Lin-Wei-Ying-Yang model. Investigator-reported System Organ Class terms were used to classify cause-specific hospitalisations. The trial is registered with ClinicalTrials.gov, NCT01730534.FindingsBetween April 25, 2013, and Sept 18, 2018, 17 160 people (6422 [37·4%] women, 10 738 [62·6%] men; mean age 63·9 years [SD 6·8]) were enrolled in the original trial, of whom 10186 (59·4%) had multiple risk factors for but did not have established atherosclerotic cardiovascular disease, and 6835 (39·8%) had both no evidence of atherosclerotic cardiovascular disease and low KDIGO risk. Over a median follow-up of 4·2 years (IQR 3·9–4·4), dapagliflozin was associated with a lower risk of first non-elective hospitalisation for any cause (2779 [32·4%] of 8582 people in the dapagliflozin group vs 3036 [35·4%] of 8578 people in the placebo group; hazard ratio [HR] 0·89 [95% CI 0·85–0·94]) and total (first plus subsequent) non-elective hospitalisations for any cause (risk ratio 0·92 [95% CI 0·86–0·97]). The association between dapagliflozin use and the risk of first non-elective hospitalisation for any cause was consistent in subgroups of participants with (HR 0·92 [95% CI 0·85–0·99] and without (0·87 [0·81–0·94]) atherosclerotic cardiovascular disease at baseline (p interaction=0·31). Compared with the placebo group, the dapagliflozin group had lower risk of first hospitalisations due to cardiac disorders (HR 0·91 [95% CI 0·84–1·00]), metabolism and nutrition disorders (0·73 [0·60–0·89]), renal and urinary disorders (0·61 [0·49–0·77]), and due to any other cause excluding these three causes (0·90 [0·85–0·96]). Treatment with dapagliflozin was also associated with a lower risk of hospitalisations due to musculoskeletal and connective tissue disorders (HR 0·81 [0·67–0·99]) and infections and infastations (HR 0·86 [0·78–0·96]).InterpretationDapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on health-care costs attributable this condition.

Published
2023

18. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Author

Fitter, Heather D., Illoh, Kachikwu, Cavanaugh, Kenneth J., Jr., Scirica, Benjamin M., Irony, Ilan, Brown Kichline, Rachel E., Levine, Jonathan G., Park, Anna, Sacks, Leonard, Szarfman, Ana, Unger, Ellis F., Wachter, Lori Ann, Zuckerman, Bram, Mitchel, Yale, Peddicord, Douglas, Shook, Thomas, Kisler, Bron, Jaffe, Charles, Bartley, Rhonda, DeMets, David L., Mencini, MariJo, Janning, Cheri, Bai, Steve, Lawrence, John, D’Agostino, Ralph B., Sr., Pocock, Stuart J., Hicks, Karen A., Mahaffey, Kenneth W., Mehran, Roxana, Nissen, Steven E., Wiviott, Stephen D., Dunn, Billy, Solomon, Scott D., Marler, John R., Teerlink, John R., Farb, Andrew, Morrow, David A., Targum, Shari L., Sila, Cathy A., Thanh Hai, Mary T., Jaff, Michael R., Joffe, Hylton V., Cutlip, Donald E., Desai, Akshay S., Lewis, Eldrin F., Gibson, C. Michael, Landray, Martin J., Lincoff, A. Michael, White, Christopher J., Brooks, Steven S., Rosenfield, Kenneth, Domanski, Michael J., Lansky, Alexandra J., McMurray, John J.V., Tcheng, James E., Steinhubl, Steven R., Burton, Paul, Mauri, Laura, O’Connor, Christopher M., Pfeffer, Marc A., Hung, H.M. James, Stockbridge, Norman L., Chaitman, Bernard R., and Temple, Robert J.

Published
2018
Full Text
View/download PDF

20. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58

Author

Berg, David, Wiviott, Stephen D, RAZ, Itamar, Kamanu, Frederick, Im, KyungAh, Cahn, Avivit, Mosenzon, ofri, Bhatt, Deepak L, Jarolim, Petr, Leiter, Lawrence A, McGuire, Darren K, WILDING, JOHN, Huo, Yong, Lopez-sendon, Jose L, Ardissino, Diego, Gause-nilsson, Ingrid A, Sabatine, Marc S, and Morrow, David A

Published
2020
Full Text
View/download PDF

21. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

Author

Zelniker, Thomas A, Morrow, David A, Mosenzon, ofri, Goodrich, Erica, Jarolim, Petr, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, WILDING, JOHN, Averkov, Oleg V, Budaj, Andrzej, Parkhomenko, Alexander, Ray, Kausik K, Gause-nilsson, Ingrid A, Langkilde, Anna Maria, Fredriksson, Martin, RAZ, Itamar, Sabatine, Marc S, and Wiviott, Stephen D

Published
2020
Full Text
View/download PDF

26. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

Author

Bonaca, Marc P., Wiviott, Stephen D., Zelniker, Thomas A., Mosenzon, Ofri, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Goodrich, Erica L., De Mendonca Furtado, Remo Holanda, Wilding, John P.H., Cahn, Avivit, Gause-Nilsson, Ingrid A.M., Johanson, Per, Fredriksson, Martin, Johansson, Peter A., Langkilde, Anna Maria, Raz, Itamar, and Sabatine, Marc S.

Published
2020
Full Text
View/download PDF

27. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Author

Zelniker, Thomas A., Bonaca, Marc P., Furtado, Remo H.M., Mosenzon, Ofri, Kuder, Julia F., Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Budaj, Andrzej, Kiss, Robert G., Padilla, Francisco, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2020
Full Text
View/download PDF

30. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58

Author

Small, Andre M., primary, Berg, David, additional, Raz, Itamar, additional, Goodrich, Erica L., additional, Moura, Filipe, additional, Mosenzon, Ofri, additional, Cahn, Avivit, additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John, additional, Gause-Nilsson, Ingrid, additional, Sabatine, Marc Steven, additional, Morrow, David A., additional, and Wiviott, Stephen D., additional

Published
2023
Full Text
View/download PDF

31. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Author

Gaba, Prakriti, primary, O’Donoghue, Michelle L., additional, Park, Jeong-Gun, additional, Wiviott, Stephen D., additional, Atar, Dan, additional, Kuder, Julia F., additional, Im, KyungAh, additional, Murphy, Sabina A., additional, De Ferrari, Gaetano M., additional, Gaciong, Zbigniew A., additional, Toth, Kalman, additional, Gouni-Berthold, Ioanna, additional, Lopez-Miranda, Jose, additional, Schiele, François, additional, Mach, François, additional, Flores-Arredondo, Jose H., additional, López, J. Antonio G., additional, Elliott-Davey, Mary, additional, Wang, Bei, additional, Monsalvo, Maria Laura, additional, Abbasi, Siddique, additional, Giugliano, Robert P., additional, and Sabatine, Marc S., additional

Published
2023
Full Text
View/download PDF

34. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Author

Bonaca, Marc P., Olenchock, Benjamin A., Salem, Joe-Elie, Wiviott, Stephen D., Ederhy, Stephane, Cohen, Ariel, Stewart, Garrick C., Choueiri, Toni K., Di Carli, Marcelo, Allenbach, Yves, Kumbhani, Dharam J., Heinzerling, Lucie, Amiri-Kordestani, Laleh, Lyon, Alexander R., Thavendiranathan, Paaladinesh, Padera, Robert, Lichtman, Andrew, Liu, Peter P., Johnson, Douglas B., and Moslehi, Javid

Published
2019
Full Text
View/download PDF

35. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Author

Kato, Eri T., Silverman, Michael G., Mosenzon, Ofri, Zelniker, Thomas A., Cahn, Avivit, Furtado, Remo H.M., Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Bonaca, Marc P., Ruff, Christian T., Desai, Akshay S., Goto, Shinya, Johansson, Peter A., Gause-Nilsson, Ingrid, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2019
Full Text
View/download PDF

36. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

Author

Furtado, Remo H.M., Bonaca, Marc P., Raz, Itamar, Zelniker, Thomas A., Mosenzon, Ofri, Cahn, Avivit, Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Ruff, Christian T., Nicolau, Jose C., Gause-Nilsson, Ingrid A.M., Fredriksson, Martin, Langkilde, Anna Maria, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2019
Full Text
View/download PDF

37. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Author

Zelniker, Thomas A., Wiviott, Stephen D., Raz, Itamar, Im, KyungAh, Goodrich, Erica L., Furtado, Remo H.M., Bonaca, Marc P., Mosenzon, Ofri, Kato, Eri T., Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., and Sabatine, Marc S.

Published
2019
Full Text
View/download PDF

40. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Author

Pollack, Rena, primary, Raz, Itamar, additional, Wiviott, Stephen D., additional, Goodrich, Erica L., additional, Murphy, Sabina A., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Mosenzon, Ofri, additional, Langkilde, Anna Maria, additional, Gause-Nilsson, Ingrid A.M., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P.H., additional, Sabatine, Marc S., additional, and Cahn, Avivit, additional

Published
2022
Full Text
View/download PDF

41. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

Author

Bohula, Erin A., primary, Berg, David D., additional, Lopes, Mathew S., additional, Connors, Jean M., additional, Babar, Ijlal, additional, Barnett, Christopher F., additional, Chaudhry, Sunit-Preet, additional, Chopra, Amit, additional, Ginete, Wilson, additional, Ieong, Michael H., additional, Katz, Jason N., additional, Kim, Edy Y., additional, Kuder, Julia F., additional, Mazza, Emilio, additional, McLean, Dalton, additional, Mosier, Jarrod M., additional, Moskowitz, Ari, additional, Murphy, Sabina A., additional, O’Donoghue, Michelle L., additional, Park, Jeong-Gun, additional, Prasad, Rajnish, additional, Ruff, Christian T., additional, Shahrour, Mohamad N., additional, Sinha, Shashank S., additional, Wiviott, Stephen D., additional, Van Diepen, Sean, additional, Zainea, Mark, additional, Baird-Zars, Vivian, additional, Sabatine, Marc S., additional, Morrow, David A., additional, Im, Kyung Ah, additional, Saxena, Retu, additional, Wiley, Brandon, additional, Benson, Carina, additional, Delamed, Roman, additional, Skeik, Nedaa, additional, Chopra, Ami, additional, Judson, Marc, additional, Beegle, Scott, additional, Shkolnik, Boris, additional, Tiwari, Anupama, additional, Wu, Gregory, additional, Raval, Abhijit, additional, Branch, Emerald, additional, Rischard, Franz, additional, Hypes, Cameron, additional, Bixby, Billie, additional, Bime, Christian, additional, Sundaram, Madhan, additional, Sweitzer, Nancy, additional, Sandoval, Alfredo Vazquez, additional, White, Heath, additional, Berg, Katherine, additional, Shaefi, Shahzad, additional, Donnino, Michael, additional, Carroll, Brett, additional, Ieong, Michael, additional, Ackerbauer, Kimberly, additional, Murphy, Jaime, additional, Bhatt, Ankeet, additional, Blood, Alexander, additional, Patel, Siddharth, additional, Luu, Victor, additional, Narechania, Shraddha, additional, Lorganger, Austin, additional, Plambeck, Robert, additional, Nayfeh, Ali, additional, Sanley, Michael, additional, Del Cor, Michel, additional, Hegg, AJ, additional, Nara, Winston, additional, Snyder, Michael, additional, Khan, Faisal, additional, Shawa, Imad, additional, Larned, Joshua, additional, Collado, Elias, additional, Al Faiyumi, Mohammed, additional, Mehta, Rajeev, additional, Komanapalli, Sudarshan, additional, Muppidi, Vijayadershan, additional, Desai, Mehul, additional, Flanagan, Casey, additional, Genovese, Leonard, additional, Haddad, Tariq, additional, King, Christopher, additional, Peterson, Amber, additional, Htun, Thane, additional, Pionk, Elizabeth, additional, Mouawad, Nicolas, additional, Kumar, Chintalapudi, additional, Nguyen, Kevin, additional, Mughal, Majid, additional, Malek, Ryan, additional, Parekh, Akarsh, additional, Provenzano, Christopher, additional, Ianitelli, Melissa, additional, Prentice-Gaytan, Nicole, additional, Bykowski, Adam, additional, Tait, Don, additional, Schendel, Shelley, additional, Yalamanchili, Varun, additional, Lala, Vasim, additional, Hunyadi, Victor, additional, Papolos, Alexander, additional, Kenigsberg, Benjamin, additional, Shenoy, Aarthi, additional, Stuckey, Thomas, additional, McQuaid, Douglas, additional, Mannam, Praveen, additional, McClung, Jeffrey, additional, Nilsson, Kent, additional, McKown, Andrew, additional, Wells, Jason, additional, Hotchkin, David, additional, Jacobs, Marc, additional, Strauss, Wayne, additional, Balestra, Rick, additional, Sahni, Vikram, additional, Snell, R. Jeffrey, additional, Suradi, Hussam, additional, Sungurlu, Sarah, additional, Kuppy, Jessica, additional, Gajo, Eileen, additional, Adams, Foster, additional, Shehadeh, Abbas, additional, Suleiman, Addi, additional, Nandigam, Harish, additional, Slim, Jihad, additional, Babar, Sardar Ijlal, additional, Baral, Dipti, additional, Nawaz, Talha, additional, Waheed, Syed Abdullah, additional, Roth, Randy, additional, Sitaula, Subhas, additional, Hayat, Shahid, additional, Babu, Jooby, additional, Caberto, Jason, additional, Hsu, Victor, additional, Chang, Robert, additional, Bochan, Markian, additional, Garcia-Cortes, Rafael, additional, Skopicki, Hal, additional, Chen, On, additional, Pilato, Lauren, additional, Richman, Paul, additional, Adler, Alexander, additional, Sudhindra, Praveen, additional, Beversdorf, Jamie, additional, Kashyap, Ravindra, additional, Mehta, Parth, additional, Mehrad, Borna, additional, Ataya, Ali, additional, Lascano, Jorge, additional, Brantly, Mark, additional, Austin, Adam, additional, Koman, Eduard, additional, Galski, Thomas, additional, Kumar, Vijaya, additional, Soubani, Ayman, additional, Harrison, Nicolas, additional, Reddy, Vineet, additional, and Fonkam, Audrey, additional

Published
2022
Full Text
View/download PDF

44. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis

Author

Kato, Eri Toda, primary, Morrow, David A, additional, Guo, Jianping, additional, Berg, David D, additional, Blazing, Michael A, additional, Bohula, Erin A, additional, Bonaca, Marc P, additional, Cannon, Christopher P, additional, de Lemos, James A, additional, Giugliano, Robert P, additional, Jarolim, Petr, additional, Kempf, Tibor, additional, Kristin Newby, L, additional, O’Donoghue, Michelle L, additional, Pfeffer, Marc A, additional, Rifai, Nader, additional, Wiviott, Stephen D, additional, Wollert, Kai C, additional, Braunwald, Eugene, additional, and Sabatine, Marc S, additional

Published
2022
Full Text
View/download PDF

45. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Author

O’Donoghue, Michelle L., primary, Giugliano, Robert P., additional, Wiviott, Stephen D., additional, Atar, Dan, additional, Keech, Anthony, additional, Kuder, Julia F., additional, Im, KyungAh, additional, Murphy, Sabina A., additional, Flores-Arredondo, Jose H., additional, López, J. Antonio G., additional, Elliott-Davey, Mary, additional, Wang, Bei, additional, Monsalvo, Maria Laura, additional, Abbasi, Siddique, additional, and Sabatine, Marc S., additional

Published
2022
Full Text
View/download PDF

46. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Author

Mosenzon, Ofri, primary, Raz, Itamar, additional, Wiviott, Stephen D., additional, Schechter, Meir, additional, Goodrich, Erica L., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Murphy, Sabina A., additional, Zelniker, Thomas A., additional, Langkilde, Anna Maria, additional, Gause-Nilsson, Ingrid A.M., additional, Fredriksson, Martin, additional, Johansson, Peter A., additional, Wilding, John P.H., additional, McGuire, Darren K., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, Cahn, Avivit, additional, Dwyer, Jamie P., additional, Heerspink, Hiddo J.L., additional, and Sabatine, Marc S., additional

Published
2022
Full Text
View/download PDF

47. Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention: A TRITON–TIMI 38 Subgroup Analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction 38)

Author

Udell, Jacob A., Braunwald, Eugene, Antman, Elliot M., Murphy, Sabina A., Montalescot, Gilles, and Wiviott, Stephen D.

Published
2014
Full Text
View/download PDF

48. Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel: An Analysis From the TRITON–TIMI 38 Study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38)

Author

Kohli, Payal, Udell, Jacob A., Murphy, Sabina A., Cannon, Christopher P., Antman, Elliott M., Braunwald, Eugene, and Wiviott, Stephen D.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results